title: [Management of duodenal adenomatosis in patients with familial adenomatous polyposis].
abstract: OBJECTIVE
  To review our global management of duodenal adenomas in patients with familial adenomatous polyposis and report the results of different therapeutic approaches. To present the outcome and possible sequels of pancreaticoduodenectomy.
  
  
  METHODS
  We identified five cases of duodenal adenomas in patients with familial adenomatous polyposis over a period of 10 years (1992-2001), we followed the progression of their Spigelman score. Results of conservative and surgical treatment were collected.
  
  
  RESULTS
  Duodenal adenomas were discovered 5-33 years after the first operation for colonic polyposis. The score of Spigelman was as follows: 2, stage 2; 3, stage 3; 1, stage 4. Endoscopic laser therapy followed by Sulindac prescription was proposed in three cases, with only one success. Duodenopancreatectomy was performed in four patients: once the diagnosis of adenoma was made in one patient, due to Spigelman stage 4 with severe dysplasia, because development of intramucosal carcinoma under surveillance in one patient, and after failure or complication of conservative treatment in two others. Worsening of Spigelman score was observed in two out of four patients submitted to conservative therapy. Correlation between Spigelman score and final examination of the specimen was correct in two cases. There was neither significant morbidity nor long-term nutritional sequel after pancreaticoduodenectomy.
  
  
  CONCLUSIONS
  Duodenal adenomas may recur or progress into malignant degeneration under conservative treatment. The pancreaticoduodenectomy is an acceptable solution for stage 4 of Spigelman, especially when severe dysplasia is present.
authors.affiliation: Hôpital général de Makassed, Riad El-Solh, P.O.Box 11-6301, Beyrouth, Liban.
authors.forename: H
authors.initials: H
authors.lastname: Fawal
authors.forename: L
authors.initials: L
authors.lastname: Gambiez
authors.forename: A
authors.initials: A
authors.lastname: Raad
authors.forename: F R
authors.initials: FR
authors.lastname: Pruvot
authors.forename: J P
authors.initials: JP
authors.lastname: Chambon
authors.forename: A
authors.initials: A
authors.lastname: Saudemont
authors.forename: P
authors.initials: P
authors.lastname: Quandalle
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000175:diagnosis / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D002648:Child; D003082:Colectomy; D003125:Colostomy; D004379:Duodenal Neoplasms / Q000175:diagnosis / Q000628:therapy*; D004384:Duodenoscopy / Q000009:adverse effects / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007081:Ileostomy; D053685:Laser Therapy / Q000009:adverse effects / Q000379:methods; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009367:Neoplasm Staging; D016577:Pancreaticoduodenectomy / Q000009:adverse effects / Q000379:methods; D011379:Prognosis; D013467:Sulindac / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013467:Sulindac